ZARAgoza DEMentia DEPression Project
The main objective is to document the association between hypothesized risk factors and cases of dementia (and depression) and its most frequent subtypes, dementia of the Alzheimer’s type (DAT) and vascular dementia (VD).
The secondary objectives are:in the first place, to document related cultural aspects like: the course and natural history of both dementia and depression in this population; the prevalence, incidence and associations of disability; the prevalence, incidence and implications of physical morbidity, as well as non-cognitive, non-depressive morbidity; and the mortality outcomes and factors influencing them. Secondly, its objective is to compare incidence rates of dementia, as well as depression, and risk factors for both conditions. Finally, ZARADEMP aims to document the prevalence and incidence of physical and psychiatric co-morbidity, as well as its associations and related risk factors.
Overview
- Acronym
- ZARADEMP
- Investigators
-
- Contacts
-
General Design
- Study design
- Cohort
- Start - End Year
- 1994 - 2015
- General Information on Follow Up (profile, frequency)
-
The baseline was a cross-sectional study and the two waves followed-up (2 and 4 years later, respectively) with the cohort of cognitively intact individuals.
- Recruitment Target
-
- Individuals
- Number of Participants
- 4,803
- Number of Participants with Biological Samples
- 500
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Marker Paper
Lobo A., Saz P., Marcos G. et al. Prevalence of dementia in a southern European population in two different time periods: the ZARADEMP Project.. The context and the objectives. Acta Psychiatr Scand. 2007 Oct;116(4):299-307.
PUBMED 17803760Timeline
Population
The population consists of men and women aged 55 years or more living in the city of Zaragoza, Spain.
Selection Criteria
- Minimum age
-
55
- Countries
-
- Spain
- Territory
-
Zaragoza
Sources of Recruitment
- General Population
-
- Selected sample
Sample Size
- Number of Participants
- 4,803
- Supplementary information about number of participants
-
Zarademp I: 4803 participants
Zarademp II: 3237 participants
Zarademp III: 2403 participants
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | ZARADEMP - Wave I |
|
1994 (September) | 1994 (November) | |
| 1 | ZARADEMP - Wave II |
|
1997 (January) | 1997 (March) | |
| 2 | ZARADEMP - Wave III |
|
1999 (May) | 1999 (July) |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
Areas of Information Collected per per Population and Data Collection Event
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|